If FOXM1 upregulation in MPNSTs does mediate acquired resistance to CDK4/6 and/or MEK inhibition, pharmacologically blocking FOXM1 activity in combination with drugs targeting MEK and CDK4/6 could be highly effective in achieving sustained MPNST regression. The gene discussed is CDK4; the disease is malignant peripheral nerve sheath tumor.